Snail Games to Present at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, at 4:00 p.m. ET

CULVER CITY, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) ("Snail Games"), a leading independent global developer and publisher of interactive digital entertainment, today announced it will be presenting and holding one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14-16, 2026, at the Lotte New York Palace Hotel, New York City.

Snail Games’ management is scheduled to present on Monday, September 14, 2026, at 4:00 p.m. Eastern time. Snail Games’ management will also be available for one-on-one meetings during the conference. 

The presentation will be available for viewing online via webcast here.

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

About H.C. Wainwright & Co.
H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors.
For more information visit H.C. Wainwright & Co. at www.hcwco.com.

Snail, Inc. Investor Relations:
Gateway Group, Inc.
John Yi and Steven Shinmachi
949-574-3860
[email protected]

You May Also Be Interested In

• 4th "From Ziquejie Terraces To The World" Global Farming Culture Exchange and Mutual Learning Conference Opens in Loudi, Hunan
• The Law Offices of Eric A. Rudolph Proudly Sponsors Boo2Bullying's 4th Annual "Kick Bullying to the Curb" Event in Palm Springs
• Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity